<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37148311</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-0584</ISSN><JournalIssue CitedMedium="Internet"><Volume>102</Volume><Issue>8</Issue><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Annals of hematology</Title><ISOAbbreviation>Ann Hematol</ISOAbbreviation></Journal><ArticleTitle>Rare acquired factor V inhibitors combined with positive lupus anticoagulant that successfully treated by plasmapheresis and prednisone acetate: a typical case report.</ArticleTitle><Pagination><StartPage>2271</StartPage><EndPage>2273</EndPage><MedlinePgn>2271-2273</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00277-023-05244-z</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Ning</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Intensive Care, The Second Hospital of Hebei Medical University, No. 215 Heping West Road, Xinhua District, Shijiazhuang, Hebei, 050000, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xiaojun</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Hematology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050000, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Chao</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Intensive Care, The Second Hospital of Hebei Medical University, No. 215 Heping West Road, Xinhua District, Shijiazhuang, Hebei, 050000, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tian</LastName><ForeName>Wenbin</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Intensive Care, The Second Hospital of Hebei Medical University, No. 215 Heping West Road, Xinhua District, Shijiazhuang, Hebei, 050000, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Weihao</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050000, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Ya</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Intensive Care, The Second Hospital of Hebei Medical University, No. 215 Heping West Road, Xinhua District, Shijiazhuang, Hebei, 050000, People's Republic of China. md2006liuya@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Ann Hematol</MedlineTA><NlmUniqueID>9107334</NlmUniqueID><ISSNLinking>0939-5555</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016682">Lupus Coagulation Inhibitor</NameOfSubstance></Chemical><Chemical><RegistryNumber>VB0R961HZT</RegistryNumber><NameOfSubstance UI="D011241">Prednisone</NameOfSubstance></Chemical><Chemical><RegistryNumber>9001-24-5</RegistryNumber><NameOfSubstance UI="D005165">Factor V</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000085">Acetates</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016682" MajorTopicYN="Y">Lupus Coagulation Inhibitor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011241" MajorTopicYN="N">Prednisone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005165" MajorTopicYN="N">Factor V</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010956" MajorTopicYN="N">Plasmapheresis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000085" MajorTopicYN="N">Acetates</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>6</Day><Hour>19</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>6</Day><Hour>14</Hour><Minute>48</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37148311</ArticleId><ArticleId IdType="doi">10.1007/s00277-023-05244-z</ArticleId><ArticleId IdType="pii">10.1007/s00277-023-05244-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ang AL, Kuperan P, Ng CH, Ng HJ (2009) Acquired factor V inhibitor. A problem-based systematic review. Thromb Haemost 101(5):852&#x2013;859. https://doi.org/10.1160/th08-11-0767</Citation><ArticleIdList><ArticleId IdType="doi">10.1160/th08-11-0767</ArticleId><ArticleId IdType="pubmed">19404538</ArticleId></ArticleIdList></Reference><Reference><Citation>Park GH, Kim S, Kim MS, Yu YM, Kim GH, Lee JS et al (2019) The association between cephalosporin and hypoprothrombinemia: a systematic review and meta-analysis. Int J Environ Res Public Health 16(20):3937. https://doi.org/10.3390/ijerph16203937</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph16203937</ArticleId><ArticleId IdType="pubmed">31623191</ArticleId><ArticleId IdType="pmc">6843226</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui QY, Shen HS, Wu TQ, Chen HF, Yu ZQ, Wang ZY (2015) Development of acquired factor V inhibitor after treatment with ceftazidime: a case report and review of the literature. Drug Des Devel Ther 9:2395&#x2013;2398. https://doi.org/10.2147/dddt.S68682</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/dddt.S68682</ArticleId><ArticleId IdType="pubmed">25987837</ArticleId><ArticleId IdType="pmc">4422287</ArticleId></ArticleIdList></Reference><Reference><Citation>Sridharan M, Fylling KA, Ashrani AA, Chen D, Marshall AL, Hook CC et al (2018) Clinical and laboratory diagnosis of autoimmune factor V inhibitors: a single institutional experience. Thromb Res 171:14&#x2013;21. https://doi.org/10.1016/j.thromres.2018.09.044</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2018.09.044</ArticleId><ArticleId IdType="pubmed">30227314</ArticleId></ArticleIdList></Reference><Reference><Citation>Olson NJ, Ornstein DL (2017) Factor V inhibitors: a diagnostic and therapeutic challenge. Arch Pathol Lab Med 141(12):1728&#x2013;1731. https://doi.org/10.5858/arpa.2016-0445-RS</Citation><ArticleIdList><ArticleId IdType="doi">10.5858/arpa.2016-0445-RS</ArticleId><ArticleId IdType="pubmed">29189062</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen AJ, Kessler CM (1995) Treatment of inherited coagulation disorders. Am J Med 99(6):675&#x2013;682. https://doi.org/10.1016/s0002-9343(99)80256-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0002-9343(99)80256-3</ArticleId><ArticleId IdType="pubmed">7503092</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu YX, Kaufman R, Rudolph AE, Collum SE, Blinder MA (1996) Multimodality therapy of an acquired factor V inhibitor. Am J Hematol 51(4):315&#x2013;318. https://doi.org/10.1002/(sici)1096-8652(199604)51:4&lt;315::aid-ajh11&gt;3.0.co;2-d</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(sici)1096-8652(199604)51:4&lt;315::aid-ajh11&gt;3.0.co;2-d</ArticleId><ArticleId IdType="pubmed">8602633</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada S, Asakura H (2020) Acquired factor V inhibitor. Rinsho Ketsueki 61(7):791&#x2013;798. https://doi.org/10.11406/rinketsu.61.791</Citation><ArticleIdList><ArticleId IdType="doi">10.11406/rinketsu.61.791</ArticleId><ArticleId IdType="pubmed">32759567</ArticleId></ArticleIdList></Reference><Reference><Citation>Theron A, Burcheri S, Vacheret F, Hillaire-Buys D, Sauguet P, Schved JF et al (2017) Iatrogenic acquired factor V inhibitors: a case report and review of the French pharmacovigilance database. Thromb Res 157:154&#x2013;156. https://doi.org/10.1016/j.thromres.2017.06.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2017.06.007</ArticleId><ArticleId IdType="pubmed">28755628</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>